This company is no longer actively trading as an independent public company (delisted, acquired, or ceased operations). This profile is retained for reference.
Wellbeing Digital Sciences Inc. is an evidence-based mental healthcare company focused on the development and implementation of innovative clinical treatment solutions, including psychedelic medicine and digital therapeutics, as supported by clinical research. Its mission is supported by a network of North American clinics that provide forward-thinking therapies and other types of treatment to patients as well as through a contract research organization that offers clinical trials services to clients pursuing drug development.
Previously named Ketamine One Capital Limited; formerly Myconic Capital Corp.
Stock Performance
Wellbeing Digital Services News 31 articles
- Revitalist Lifestyle and Wellness Ltd. Partners with Wake Network to Launch Lion’s Brain Supplements for Enhanced Mental Clarity and Wellbeing
- Cory Firth is Committed to a Career Empowering Wellbeing – Podcast Episode #44
- Psyence Group Inc Subsidiary Psyence Biomedical Ltd. announces signing of definitive agreement for a convertible note in connection with planned business combination
- aNUma: Pioneering Psychological Wellbeing Technology for Serious Disease Care and Beyond
- Beckley Retreats Announces Expanded Scholarship Program, Alongside New Specialty Programs for Underserved Communities
- Beckley Retreats Launches Signature Program for Personal Discovery and Transformation
- Psyence Group Announces Resignation of Board Member
- Psyence Group Announces SEC Effectiveness of F-4 for Proposed Business Combination Between Subsidiary and Nasdaq Listed Newcourt Acquisition Corp
- Psyence Expands Psilocybin Production Capability
- Beckley Retreats Advances Research to Combat Veteran Suicide Through Psychedelic Retreats
- Wellbeing Subsidiary KGK Science Receives Approval for First-of-its-Kind Psylocibin Clinical Trial
- Wellbeing Subsidiary KGK Science Submits CTA for Phase IIA Clinical Trial
- Wellbeing Subsidiary Mindscape Treats its 1,000th Patient
- Wellbeing Digital Announces Resignation of Directors
- Wellbeing Subsidiary KGK Science Enters into Research Contract With Nova Mentis for Phase II A Clinical Trial
- Wellbeing Announces Dfinitive Agreement to Divest IRP Health
- Wellbeing Digital to Participate at this Years’ Wonderland Miami Conference
- Tim Schlidt is Funding a New Paradigm in Wellbeing – Podcast Episode #22
- Wellbeing Digital Subsidiary KGK to Participate in the Supply Side West Conference
- Wellbeing Digital and Subsidiary KGK Science Applauds the Government of Alberta’s Move to Regulate the Use of Psychedelics
- Wellbeing Subsidiary KGK Science Announces Psilocybin Microdose Capsule Formulation to be Submitted to Health Canada for Phase 2A Trial
- Wellbeing Digital Signs LOI Manage Additional Clinics
- Wellbeing Subsidiary KGK Science Opens New Clinical Research Center to Reimagine a Healthier Future
- Wellbeing Digital Reports Financial Results for the Fourth Fiscal Quarter
- Wellbeing’ CEO Joins Benzinga’s Psychedelic Advisory Board
- Wellbeing Subsidiary KGK Science Announces AKL No Objection Status for ProGo Branded Ingredient from FDA
- Ketamine One Signs LOI for Two Ketamine Infusion Clinics in Texas
- Ketamine One Establishes Medical Advisory Board
- Ketamine One Subsidiary KGK Science Secures Multiple New Contracts
- Ketamine One to Provide Scent-Enabled Virtual Reality Via Exclusive Agreement for Psychedelic Molecules With OVR Technology
- The Chopra Foundation and MindMed to Partner on the Future of Psychedelic Medicines & Mental Wellbeing